Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Plasmodium falciparum late liver stage parasite refers to the developmental phase of the malaria parasite within human hepatocytes, occurring after sporozoite invasion and before release of merozoites into the bloodstream. This stage is critical for parasite replication and maturation, ultimately leading to symptomatic blood-stage infection. Targeting molecules specific or essential to the *P. falciparum* late liver stage offers several advantages, including preventing onset of clinical malaria and limiting potential transmission. Key proteins include LSA-1, Mei2, PTEX150, and EXP2.
Inhibition of parasite replication and maturation within hepatocytes, preventing progression to blood-stage infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum Late Liver Stage Parasite (N/A).